{"id":951601,"date":"2026-04-15T09:06:58","date_gmt":"2026-04-15T13:06:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/"},"modified":"2026-04-15T09:06:58","modified_gmt":"2026-04-15T13:06:58","slug":"cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/","title":{"rendered":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026"},"content":{"rendered":"
\n

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.<\/a>\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced\u00a0that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026<\/a>, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026.<\/p>\n

\n
\n Poster Presentation Details:<\/u>
\n <\/strong>\n <\/p>\n

\n Title<\/strong>: CUE-401: A Novel Bifunctional TGF-beta\/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of Autoimmunity
Presenter: <\/strong>Natasha M. Girgis, Director, Translational Pharmacology
Date and Time: <\/strong>Saturday, April 18, 2026, 11:30 a.m. \u2013\u00a012:30 p.m. EDT
Poster Number: <\/strong>733
Session: <\/strong>Therapeutics for Autoimmune Diseases II
Location<\/strong>: Exhibit Hall<\/p>\n

As part of the presentation, Dr. Girgis will discuss new in vivo data that supports CUE-401\u2019s ability to induce FOXP3+ antigen-specific induced T regulatory cells (iTregs) from FOXP3- conventional CD4+ T cells\u00a0through the coordinated delivery of\u00a0TGF-\u03b2 and\u00a0interleukin-2 (IL-2) signals. This new and promising preclinical data supports CUE-401\u2019s therapeutic potential to restore immune homeostasis in autoimmune and inflammatory diseases.<\/p>\n

\n About CUE-401<\/strong>
\n
CUE-401\u00a0is\u00a0a novel bifunctional therapeutic\u00a0that incorporates an innovative TGF-beta breathing-mask moiety with Cue Biopharma\u2019s clinically validated interleukin-2 (IL-2) mutein in a single injectable biologic. The design of CUE 401 was inspired by Nobel Prize winning science in 2025 for the role of IL-2 and TGF-beta as essential components in helping establish immune tolerance by regulating FOXP3 signaling. CUE-401 is designed to promote\u00a0immune regulation and tolerance by three complementary mechanisms: 1.\u00a0Direct regulation of proinflammatory mechanisms by\u00a0TGF-beta, 2. Expansion of existing Tregs by IL-2, and 3. Conversion of FOXP3- conventional CD4+ T cells\u00a0into FOXP3+ induced Tregs through the coordinated provision of\u00a0TGF-beta\u00a0and\u00a0IL-2\u00a0signals,\u00a0both\u00a0of\u00a0which are\u00a0required for the de novo induction of FOXP3 expression.<\/p>\n

\n About\u00a0Cue Biopharma<\/strong>
\n
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body. The company\u2019s proprietary platform, Immuno-STAT\u00ae (Selective Targeting and Alteration of T cells)<\/em> and biologics are designed to harness the curative potential of the body\u2019s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company\u2019s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma\u2019s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.<\/p>\n

Headquartered in\u00a0Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.<\/p>\n

For more information please visit\u00a0www.cuebiopharma.com<\/a>\u00a0and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company\u2019s belief regarding the potential benefits and applications of its drug candidates and programs, including the company\u2019s plans to further advance its differentiating Immuno-STAT\u00ae platform and lead autoimmune and inflammatory asset, CUE-401; the company\u2019s belief that CUE-401 has the therapeutic potential to restore immune homeostasis in autoimmune and inflammatory diseases; and the company\u2019s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company\u2019s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely,\u201d \u201cpromise\u201d or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company\u2019s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company\u2019s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company\u2019s ability to maintain its collaboration with ImmunoScape; the company\u2019s limited operating history, limited cash and a history of losses; the company\u2019s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current \u201cgoing concern\u201d determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company\u2019s ability to achieve profitability; potential setbacks in the company\u2019s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company\u2019s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required\u00a0U.S. Food and Drug Administration\u00a0(\u201cFDA\u201d) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company\u2019s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company\u2019s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company\u2019s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company\u2019s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company\u2019s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n

\n Investor Contact<\/strong>
\n
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced\u00a0that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026. Poster Presentation Details: Title: CUE-401: A Novel Bifunctional TGF-beta\/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of AutoimmunityPresenter: Natasha M. Girgis, Director, Translational PharmacologyDate and Time: Saturday, April 18, 2026, 11:30 a.m. \u2013\u00a012:30 … <\/p>\n

Continue reading “Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-951601","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced\u00a0that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026. Poster Presentation Details: Title: CUE-401: A Novel Bifunctional TGF-beta\/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of AutoimmunityPresenter: Natasha M. Girgis, Director, Translational PharmacologyDate and Time: Saturday, April 18, 2026, 11:30 a.m. \u2013\u00a012:30 … Continue reading "Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T13:06:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026\",\"datePublished\":\"2026-04-15T13:06:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/\"},\"wordCount\":1113,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/\",\"name\":\"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=\",\"datePublished\":\"2026-04-15T13:06:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk","og_description":"BOSTON, April 15, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced\u00a0that it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, as part of a poster at IMMUNOLOGY2026, the annual meeting of the American Association of Immunologists (AAI) taking place in Boston, Massachusetts, April 15-19, 2026. Poster Presentation Details: Title: CUE-401: A Novel Bifunctional TGF-beta\/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for the Treatment of AutoimmunityPresenter: Natasha M. Girgis, Director, Translational PharmacologyDate and Time: Saturday, April 18, 2026, 11:30 a.m. \u2013\u00a012:30 … Continue reading \"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-15T13:06:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026","datePublished":"2026-04-15T13:06:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/"},"wordCount":1113,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/","name":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=","datePublished":"2026-04-15T13:06:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTc2NSM3NTM1NDkxIzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=951601"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951601\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=951601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=951601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=951601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}